Physicians

Dermacyte: easy-to-use, effective wound care.

Dermacyte™ is human allograft prepared from placental membrane donated after Cesarean Section delivery from volunteer donor. The tissue was retrieved and processed within 72 hours from time of C-­section. The surgical site is prepped according to AORN standards for incision disinfection. Dermacyte is processed in various sizes appropriate for surgical use, using 1.0% glutaraldehyde, and gentamicin in 0.9% NaCl and terminally sterilized using gamma irradiation (25 kGy).

Optimal Patient Profile: Discuss treatment options with patients

  • A single, full thickness foot and/or leg wound

  • Diabetic, pressure, arterial, or venous

  • Unresponsive to other therapies (e.g. periodic debridement, moist dressings, antibiotics, hyperbaric oxygen, glycemic control)

  • No clinical signs of infection

  • Wound duration 1 to 12 months

  • Typical wound size: >1 sq. cm and <25 sq. cm. ( Wound size is measured by multiplying wound length by width)

Wound Site Preparation:

  • Host bed should be devoid of debris

  • Aggressive sharp surgical debridement to healthy bleeding tissue

  • Do not use chemical debridement

  • Include Visual Application Guide image
      A. Debridement
    B. Apply amnion to wound bed
    C. Non-­adherent contact layer placed over amnion
    D. Adhesive strips secure a moisture retentive layer and a compress

Product Preparation: Handle matrix with care to preserve sterility and integrity.

  • Slowly pull apart wings of package, and aseptically pass the inner package containing the graft to the nurse / surgical assistant

  • Corner fold is over the epithelial side. The epithelial side is applied to patient’s affected area

  • When opening inner pouch, be sure to identify the epithelial-­side and maintain that orientation until implanted

  • Remove the dehydrated product from the inner pouch. Handle the amnion with care, as it is very fragile and may tear -­-­ Do not rehydrate

  • Cut (larger is better) to appropriate size based on wound size

  • The patient’s body fluids will naturally hydrate the amnion

  • Sterile saline drops may be added to make amnion more malleable once in place or to easily reposition if required

Patient Treatment: Improve the patient care experience by discussing the treatment plan

  • Initiate treatment on same day as surgical debridement

  • The allograft should be applied in a manner to prevent displacement

  • 3-­layer wound dressing after amnion placement (Include 2-layer wound image)

  • Re-­administration of amnion every 7-­14 days until wound closure

  • Consider debridement if eschar is present over wound

  • Weekly dressing change and wound cleansing with sterile normal saline (rinsing, swabbing, or irrigating)

  • Dressing can be change more frequently as needed – BE CAREFUL NOT TO DISTURB AMNION

  • Consider glycemic control, wound off-­loading, edema control

Patient Assessment: Evaluate effectiveness by tracking wound size

  • Consider weekly evaluation of patient until 1 week after complete healing

  • Patient education and support for best at-­home wound care practices (e.g. offloading and dressing changes)

  • Wound measurement evaluations should include: Length, Width, and Depth

  • Use of photographic evaluation recommended

  • The mean interval to healing after first administration of the amnion allograft was 2.6 months

Implant Tracking: Achieve regulatory compliance with implant tracking

  • Applicable regulations require implant reconciliation with recipient/patient

  • Consult your local representative to ensure each usage of Dermacyte is documented for traceability

  • Dermacyte is designed for application directly to acute and chronic wounds and is registered with the FDA for the focal treatment of localized diabetic foot ulcers. It is an easy-to-use, effective approach for addressing wound care in your practice.

  • Developed from placental membranes, Dermacyte is comprised of a matrix rich in collagen, growth factors, and optimized for bioresorption of the wound bed. The flexible conforming cover adheres to complex anatomies and is available in multiple sizes, ensuring patient comfort while reducing waste and potential cost.

  • This innovative treatment option is for therapeutic applications such as chronic diabetic foot ulcers and acute wounds, like surgical incisions, burns, and trauma. Optimal patient profile:

    • A single, full thickness foot and/or leg wound

    • Diabetic, pressure, arterial, or venous

    • Unresponsive to other therapies (e.g. periodic debridement, moist dressings, antibiotics, hyperbaric oxygen, glycemic control)

    • No clinical signs of infection

    • Wound duration 1 to 12 months

    • Typical wound size: >1 sq. cm and <25 sq. cm. ( Wound size is measured by multiplying wound length by width)

  • Dermacyte is an easy-to-use, effective regenerative wound repair matrix comprised of collagen, growth factors, and optimized for bioresorption of the wound bed.

  • When applied properly, Dermacyte has been shown to be beneficial in supporting natural wound repair and decreasing the time it takes to close chronic wounds, alleviating distress and discomfort of patients.

  • Please download the practical considerations brochure for more information on Dermacyte, patient selection, preparation and application, as well as treatment and assessment. For best patient outcomes, closely follow all directions and considerations. (Button to download the practical considerations brochure)

For more information and complete instructions, please download the Dermacyte package insert.

A step-by-step guide of clinical considerations when using Dermacyte in the treatment of wounds may also be downloaded.